TCBPW End Period Cash Flow from 2010 to 2024

TCBPW Stock  USD 0.02  0  24.67%   
TC BioPharm End Period Cash Flow yearly trend continues to be fairly stable with very little volatility. End Period Cash Flow will likely drop to about 2.3 M in 2024. During the period from 2010 to 2024, TC BioPharm End Period Cash Flow regression line of quarterly data had mean square error of 798.4 B and geometric mean of  1,223,569. View All Fundamentals
 
End Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
2.5 M
Current Value
2.3 M
Quarterly Volatility
1.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check TC BioPharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TC BioPharm's main balance sheet or income statement drivers, such as Interest Income of 1.9 K, Depreciation And Amortization of 638 K or Interest Expense of 78.9 K, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.3. TCBPW financial statements analysis is a perfect complement when working with TC BioPharm Valuation or Volatility modules.
  
Check out the analysis of TC BioPharm Correlation against competitors.

Latest TC BioPharm's End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of TC BioPharm plc over the last few years. It is TC BioPharm's End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TC BioPharm's overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

TCBPW End Period Cash Flow Regression Statistics

Arithmetic Mean1,431,302
Geometric Mean1,223,569
Coefficient Of Variation74.68
Mean Deviation724,181
Median956,495
Standard Deviation1,068,848
Sample Variance1.1T
Range4.1M
R-Value0.59
Mean Square Error798.4B
R-Squared0.35
Significance0.02
Slope141,603
Total Sum of Squares16T

TCBPW End Period Cash Flow History

20242.3 M
20232.5 M
20224.8 M
20211.6 M
2020748 K

About TC BioPharm Financial Statements

TC BioPharm investors use historical fundamental indicators, such as TC BioPharm's End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TC BioPharm. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
End Period Cash Flow2.5 M2.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TCBPW Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.